Last week’s hot topic on pulmonary hypertension was Men with SSc-associated PAH Seen to Both Develop and Advance in Disease More Quickly Than Women written by Patricia Inacio.
This article focused on a large study investigating the impact of gender in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH), a team of researchers analyzed a cohort of Canadian patients and found that the male gender is associated with shorter PAH disease duration and increased burden of SSc disease, although it does not independently impact SSc-PAH survival. The study, “Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study,” was published in the Arthritis Research & Therapy journal.
The study results suggested that gender influences the frequency of PAH, time to PAH diagnosis, PAH disease duration, and SSc disease burden. But the male gender, per se, is not an independent risk factor impacting SSc-PAH survival, as it does not independently affect survival in those diagnosed with SSc-PAH.